GlassScriptPhysician profile
Luis A Artavia
NPI 1407885577
$6,650.37
in general payments reported to CMS, 2019-2025
44 companies · $994 in 2025
The $994 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $503 · 2021: $851 · 2022: $883 · 2023: $1,248 · 2024: $1,193 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,435.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $814.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.04 | 2019-2024 | Jardiance, Ofev |
| Abbvie INC. | $559.64 | 2019-2025 | Rinvoq, Humira |
| Amgen INC. | $547.34 | 2019-2025 | Evenity, Prolia, Enbrel |
| Astrazeneca Pharmaceuticals LP | $471.87 | 2019-2025 | Breztri, Farxiga, Saphnelo |
| Lilly USA, LLC | $357.82 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $255.70 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $213.17 | 2019-2024 | |
| Novo Nordisk INC | $204.16 | 2019-2025 | Wegovy, Saxenda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.25 | 2019-2025 | Xifaxan, Trulance |
| Ucb, INC. | $181.68 | 2024-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $162.82 | 2019-2025 | |
| Shield Therapeutics INC | $154.82 | 2023-2024 | Accrufer |
| Janssen Biotech, INC. | $151.97 | 2025 | Tremfya |
| Pfizer INC. | $149.24 | 2021-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Artavia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.